Drug Type Small molecule drug |
Synonyms Duochol, Fenofibrate/Pravastatin, fenofibrate/Pravastatin + [3] |
Mechanism HMG-CoA reductase inhibitors(HMG-CoA reductase inhibitors), PPARα agonists(Peroxisome proliferator-activated receptor α agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date EU (14 Apr 2011), |
Regulation- |
Molecular FormulaC43H57ClO11 |
InChIKeyYJRSIHJMINZRLT-IYNICTALSA-N |
CAS Registry934374-67-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Dyslipidemias | KR | 27 Jul 2012 | |
Hyperlipidemia, Familial Combined | EU | 14 Apr 2011 | |
Hyperlipidemia, Familial Combined | IS | 14 Apr 2011 | |
Hyperlipidemia, Familial Combined | LI | 14 Apr 2011 | |
Hyperlipidemia, Familial Combined | NO | 14 Apr 2011 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Combined hyperlipidemia | Phase 3 | US | 01 Apr 2007 |
Not Applicable | 793 | lwhuhelajm(qoxsaohazo) = lobjzpvppp ppkaxapyom (jdupnhynua ) | - | 01 Feb 2017 | |||
(Control) | lwhuhelajm(qoxsaohazo) = ziwuwfawlp ppkaxapyom (jdupnhynua ) | ||||||
Not Applicable | 252 | ldkdzdgwrm(jlpuhgtaat) = fjjmepooni cteqojqpbk (zznzpuyzph ) | Positive | 01 Jan 2014 | |||
ldkdzdgwrm(jlpuhgtaat) = kibbwvbvlz cteqojqpbk (zznzpuyzph ) | |||||||
Not Applicable | 45 | hlzkasonng(enfoufndzw) = giezabdwya bcsklbfktm (cixjtjxlty ) View more | - | 01 Jan 2009 | |||
hlzkasonng(enfoufndzw) = qzfswlahsw bcsklbfktm (cixjtjxlty ) | |||||||
Not Applicable | 33 | ofxhzpewbx(tuczdmztir) = qzqexocjmm gwywfmryeg (pfetosfadr ) | Negative | 01 Jan 2005 | |||
Placebo | ofxhzpewbx(tuczdmztir) = xtlfqgnmjt gwywfmryeg (pfetosfadr ) | ||||||
Not Applicable | 9,014 | yfrwevxfcy(pqgbhrfkhx) = tqwiqgckvw rqeolrwaxu (atlbbfvrti ) View more | Positive | 01 Oct 2003 | |||
Placebo | yfrwevxfcy(pqgbhrfkhx) = qdfyzdhvot rqeolrwaxu (atlbbfvrti ) View more | ||||||
Not Applicable | - | - | awuaqijrts(jclvwcudmw) = phvcjmqzfz naxdehwuwq (qjqrlmmeun, 58.47) | - | 01 Jan 2003 | ||
awuaqijrts(jclvwcudmw) = vefpitqwxe naxdehwuwq (qjqrlmmeun, 40.75) | |||||||
Not Applicable | 70 | kvkimouytz(gpbxomedph) = kmfozmffiv llhpcvjunu (phibktjyhq ) View more | - | 01 Jan 2002 | |||
Phase 4 | 4,159 | parsfkcstg(wegjzavmen): reduction = 32 (95% CI, 4 - 52), P-Value = 0.03 View more | Positive | 19 Jan 1999 | |||
Placebo | |||||||
Phase 4 | 151 | gmvhcfdgit(tnsumykkru) = Active treatment was also associated with a reduction of any fatal event plus nonfatal myocardial infarction (p = 0.04) rztsuyowyn (safiblgzlv ) View more | - | 01 Mar 1995 | |||
Placebo |